scispace - formally typeset
S

Sheela Hanasoge

Researcher at University of Michigan

Publications -  8
Citations -  458

Sheela Hanasoge is an academic researcher from University of Michigan. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 4, co-authored 5 publications receiving 430 citations.

Papers
More filters
Journal ArticleDOI

H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase.

TL;DR: It is shown that H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is induced in all phases of the cell cycle and is mediated primarily by the ATR kinase.
Journal ArticleDOI

RPA and ATR link transcriptional stress to p53

TL;DR: It is proposed that this transcription-based stress response involving RPA, ATR, and p53 has evolved as aDNA damage-sensing mechanism to safeguard cells against DNA damage-induced mutagenesis.
Journal ArticleDOI

Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo

TL;DR: These findings suggest that CI-1033 can increase the effectiveness of radiation therapy and the extent of suppression of tyrosine kinase activity by CI- 1033, rather than the amount of activity in untreated cells, seemed to be more closely associated with the efficacy of combination treatment.
Journal ArticleDOI

The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers

TL;DR: It is shown that hCdc14A is differentially expressed in human tissues and in 75 cancer cell lines examined and that it forms a complex with Cdk1/cyclin B during interphase but not during mitosis, implicate that dysregulation of hCDC14A expression may play a role in carcinogenesis.
Journal ArticleDOI

Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases.

TL;DR: Thirty-two in 2 Gy daily fractions can be delivered safely when combined with HA chemotherapy and subsequent transarterial chemoembolization, however, although objective responses were observed, this combination was not significantly better than prior approaches.